Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that new data on its multiple sclerosis (MS) program, including COPAXONE® (glatiramer acetate injection), a product …
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S.
Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are diving nearly 15% in Wednesday’s trading session, following the news that competitor Mylan N.V.
A glimpse into why Louise Chen believes Valeant is the better biotech play than Teva down the line.
